Shares of Humana (HUM) plummeted 5.01% during Thursday's trading session, reflecting investor concerns following the company's reduced earnings outlook and potential profitability challenges.

The sharp decline came after Humana reported its second-quarter results for 2025, which showed a mixed financial performance. While the company saw increased revenues of $32.39 billion, it also experienced decreases in both net income and earnings per share compared to the same period last year. More significantly, Humana lowered its full-year 2025 GAAP EPS guidance to approximately $13.77, down from its previous outlook of $14.68.

This reduction in earnings expectations has prompted several analysts to adjust their price targets for Humana stock. Barclays raised its target price to $275 from $268, while Deutsche Bank increased its target to $250 from $224. However, these adjustments did not prevent the stock's significant drop, suggesting that investors are particularly concerned about the company's ability to maintain profitability in the face of potential challenges in the healthcare sector.

The market's reaction highlights the importance of earnings guidance and profitability metrics for healthcare companies like Humana. As the company navigates the complex landscape of Medicare Advantage and value-based care, investors will be closely watching for signs of improved cost management and operational efficiency in future quarters.